Alnylam Pharmaceuticals ALNY Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 330.7%-17.1pp | 336%-11.5pp | 340.6%-5.9pp | 343.4%-2.2pp | 347.8%+6.7pp | |
| Operating margin | 32%+49.4pp | 9.5%+30.8pp | -11.9%+17.0pp | -29.1%+11.3pp | -17.4%+94.2pp | |
| Net margin | 10.4%+51.6pp | -11.1%+36.8pp | -31%+28.7pp | -49.4%+23.9pp | -41.2%+115pp | |
| EBITDA margin | 38.8%+46.2pp | 17.5%+28.5pp | -2.8%+15.3pp | -19.1%+10.1pp | -7.4%+91.1pp | |
| Free cash flow margin | 32.3%— | 14%— | -0.4%— | —— | —— | |
| Returns | ||||||
| Return on assets | 12.1%+35.0pp | -4.4%+21.9pp | -17.3%+14.0pp | -27.4%+9.5pp | -22.9%+43.7pp | |
| Efficiency | ||||||
| Asset turnover | 3×+0.7× | 2.7×+0.4× | 2.4×+0.2× | 2.2×+0.1× | 2.3×+0.4× | |
| Inventory turnover | 31.2×+17.3× | 24.3×+12.0× | 19.6×+8.4× | 16×+5.8× | 13.9×+4.5× | |
| Liquidity | ||||||
| Current ratio | 11.2×-0.3× | 11.1×-0.6× | 11.2×-0.9× | 11.4×-1.0× | 11.6×-1.0× | |
| Quick ratio | 11×-0.3× | 10.9×-0.5× | 10.9×-0.7× | 11.1×-0.9× | 11.3×-0.9× | |
| Cash ratio | 4.2×+0.6× | 3.9×+0.5× | 3.6×+0.2× | 3.5×-0.1× | 3.6×+0.1× | |
| Leverage | ||||||
| Debt-to-equity | 2.8×— | 3.2×— | 6.9×— | 14.4×— | —— | |
| Debt-to-assets | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.3×0.0× | 0.3×0.0× | |
| Interest coverage | 6.2×+8.8× | 2.1×+5.4× | -1.5×+2.8× | -4.4×+1.5× | -2.6×+10.5× | |
| Per Share | ||||||
| Book value per share | $17.26+327% | $12.77+1,396% | $7.43+327% | $5.98+225% | $4.04+150% | |
| Valuation | ||||||
| Market capitalization | $198.56B+51.2% | $189.63B+64.6% | $167.45B+53.8% | $142.98B+49.4% | $131.34B+48.2% | |
| Enterprise value | $193.66B+50.8% | $185.43B+64.7% | $163.93B+54.0% | $139.87B+49.8% | $128.39B+48.3% | |
| Price / sales | 60.2×+1.9× | 64.9×+12.0× | 64.2×+11.7× | 62.5×+14.0× | 58.3×+3.9× | |
| Price / book | 532×— | 573.2×— | 959.1×— | 1,794.8×— | —— | |
| EV / sales | 58.8×+1.7× | 63.4×+11.8× | 62.9×+11.5× | 61.1×+13.8× | 57×+3.8× | |
| Free cash flow yield | 2.6%— | 0.9%— | -0.1%— | —— | —— | |
| Earnings yield | 1.2%+3.9pp | -0.7%+3.2pp | -2.1%+2.7pp | -3.2%+3.0pp | -2.8%+7.6pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Alnylam Pharmaceuticals's profit margins?
- Alnylam Pharmaceuticals (ALNY) runs a 81.0% gross margin and a 17.5% operating margin, with a 11.7% net margin.
- Where do Alnylam Pharmaceuticals's ratios come from?
- Every ratio is computed from Alnylam Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
